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Summary Study objective: Acute rejection (AR) of the allograft is a major clinical
problem after lungtransplantation. Repeated episodes of AR increase the risk of
developing obliterative bronchiolitis, the main cause of mortality in this patient
group. It is believed that AR is caused by T-lymphocytes reacting to donor antigens
and in turn activating antigen presenting cells (APC) such as alveolar macrophages.
Hypothetically, the interferon-g inducing cytokine IL-18 released from activated
macrophages can play a role in the development of AR by modulating cytotoxic
T-lymphocytes.
Design: To determine whether IL-18 may serve as a marker of AR, we retro-
spectively analysed the concentration of soluble IL-18 protein and inflammatory cells
in bronchoalveolar lavage fluid (BAL) from lungtransplant recipients.
Patients: To minimize confounding factors, eight pairs of patients were matched for
age, gender, pre-op diagnosis, type of operation, absence of infection and time post
transplant.
Methods: BAL levels of IL-18 (ELISA) and BAL cell differentials were analysed
before, during and after an episode of AR and compared with the matched control
group.
Conclusion: We found no changes in IL-18 concentration in BAL associated with AR.
IL-18 in BAL did not correlate with BAL lymphocyte percentage. We conclude that
change in soluble IL-18 protein does not constitute a useful marker of acute rejection
in lung allograft recipients.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Lungtransplantation has become an accepted ther-
apy for end-stage lung disease. Improvements in
organ preservation, surgical technique, immuno-
suppressive treatment and infection control have
contributed to increased graft and patient survival1
but the overall long-term prognosis is still poor.
Acute rejection of the transplanted lung is a
substantial clinical problem, since it decreases
graft survival and predisposes the patient to
chronic rejection in the form of obliterative
bronchiolitis, the main cause of mortality in this
patient group.2,3
Acute rejection is characterized by a perivascu-
lar lymphocytic infiltration in the parenchyma, with
or without concommittant lymphocytic bronchitis/
bronchiolitis.4 The diagnosis is made by a combina-
tion of histopathological assessment of transbronchial
ARTICLE IN PRESS
KEYWORDS
IL-18;
Acute rejection;
Lungtransplantation;
Bronchoalveolar lavage
*Corresponding author. Department of Respiratory Medicine,
Sahlgrenska University Hospital, G.oteborg S-413 45, Sweden.
Fax: þ 46-31-82-4904.
E-mail address: gerdt.riise@lungall.gu.se (G.C. Riise).
0954-6111/$ - see front matter & 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2003.09.007
Respiratory Medicine (2004) 98, 159–163
biopsies (TBB) and cytological assessment of
bronchoalveolar lavage (BAL).
The cellular mechanisms leading to acute rejec-
tion are only partially understood. There is evi-
dence that T-helper cells in cooperation with
antigen presenting cells (APC), such as the alveolar
macrophage, play a crucial role in the host
response to donor antigens.5,6 Since IL-18 is a
cytokine mainly produced by activated macro-
phages it may be involved in this cellular response.7
IL-18 is capable of inducing production of the TH-1
cytokine interferon-g (IFN-g) in several types of
immunocompetent cells, such as Natural Killer-
cells (NK), helper T-cells and cytotoxic T-cells,
especially in collaboration with interleukin-12).8–10
IFN-g in turn decreases the TH2 response and
enhances the TH1 response by mobilizing cytotoxic
T-cells,8,11 a phenomenon believed to be of central
importance in AR.12,13
Hypothetically, IL-18 may therefore serve as a
link between activated macrophages and IFN-g
production by cytotoxic T-cells.
In the current study, we examined whether
alterations in the concentration of soluble IL-18
protein in the airways is associated with onset of
acute allograft rejection in lungtransplant recipi-
ents. We also characterized the relationship be-
tween airway IL-18 and BAL cell populations in
these patients.
Materials and methods
Study design and subjects
In a patient material of 90 lungtransplant recipi-
ents, patients with at least one episode of acute
rejection degree XA2 were identified. Retrospec-
tive analysis of BAL fluid specimens collected
before, during and after the episode of acute
rejection was performed. The results were com-
pared with BAL sample analysis from a matched
control group.
To minimize the influence of confounding factors,
eight pairs of patients ðn ¼ 16Þ were identified and
matched for age, gender, preoperative diagnosis,
type of operation, absence of infection and time
post transplantation. Patient characteristics are
presented in Table 1.
The BAL fluid samples had been obtained for a
different study, which had been approved by the
ethical committee of the University of G .oteborg.
All subjects gave their written and oral consent. All
organs had been harvested in a similar fashion.
Organ donors and recipients were matched for
cytomegalovirus serological status. Surgical proce-
dures and immunosuppression therapy was pre-
formed as previously described.14
Postoperative follow-up
Transbronchial biopsies (TBB) and bronchoalveolar
lavage (BAL) were peformed according to the
postoperative follow-up protocol of the lung
transplant program of Sahlgrenska University Hos-
pital.15 Samples were also taken whenever clinical
signs of worsening of the patients condition
appeared such as dyspnoea, hypoxemia, decline in
forced expiratory volume in one second (FEV1)
values, radiographic infiltrate or unexpected fever.
The diagnosis of acute rejection was based on
assessment of TBB and BAL samples that were
evaluated according to the recommendations of
the Lung Rejection Study Group of the International
Society for Heart and Lung Transplantation
(ISHLT).4
Analysis of BAL samples included direct micro-
scopy for CMV inclusion bodies, Pneumocystis carini
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Table 1 Patient characteristics.
Acute rejection No rejection
Diagnosis Age Tx Gender Diagnosis Age Tx Gender
COPD 56 SL Female COPD 55 SL Female
COPD 52 SL Female COPD 52 SL Female
COPD 55 SL Male COPD 64 SL Male
PPH 53 BL Male PPH 40 BL Female
PPH 43 BL Female Eisenmenger 40 HL Female
a1-AT 50 SL Male a1-AT 51 SL Male
a1-AT 46 SL Male a1-AT 43 SL Female
Cystic fibrosis 30 BL Male Cystic fibrosis 23 BL Female
COPD: chronic obstructive pulmonary disease, PPH: primary pulmonary hypertension, a1-AT: alfa 1 antitrypsin deficiency.
Type of transplantation (Tx): SL: single lung, BL: bilateral lung, HL: heart-lung.
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(PCP), fungi and mycobacteria. In addition immu-
nocytochemistry techniques for PCP, CMV and
Legionella pneumophilia were applied. Cultures
for bacteria, including legionella and mycobacter-
ia, fungi and viruses were performed and presence
of CMV and respiratory syncytial virus (RSV) genome
was investigated by polymerase chain reaction
(PCR) amplification.
TBB were taken after collection of BAL fluid.
Four-to-six macroscopically adequate biopsies were
taken under flouroscopic guidance from the lower
and middle lobes using alligator forceps. The
biopsies were immediately placed in 10% buffered
formalin and sent for histological analysis.
Collection of samples
BAL was performed by infusing 7 20ml warmed
sterile phosphate buffered saline (PBS) solution into
a segmental middle lobe or lingula bronchus with
the bronchoscope in a wedged position. The fluid
was aspirated after each 60ml infusion, collected in
a sterile siliconized container and immediately
transported on ice to the laboratory. After filtering,
cellular components were sedimented by centrifu-
gation at 41C 200 g for 10min, and the super-
natant removed. After an additional 10-min
centrifugation at 10,000 g, the supernatant was
frozen at 701C. Cytocentrifuge slides (Shandon
Southern Products Ltd., Runcorn, UK) were made
from 100 ml aliquots of the resuspended cell pellet.
Slides were immediately fixed in 96% alcohol and
stained with May Grunwald Giemsa for later
identification of cell types on a morphological basis.
Percentages of eosinophil granulocytes (EOS), poly-
morphonuclear granulocytes (PMN), macrophages
(MD) and lymphocytes were calculated by counting
200 cells using a standard light microscope. All
samples were analysed in a blinded manner.
IL-18 protein in BAL fluid
Soluble IL-18 protein was detected using a com-
mercially available ELISA kit (Quantikine ELISA,
R&D systems, Abingdon England) in accordance
with the manufacturers instructions. The lower
detection limit was 31.2 pg/ml.
Statistical evaluation
Non-parametric analysis of variable differences
between different time points and patient groups
was performed with Kruskall–Wallis test. If signifi-
cant, further analysis with Mann–Whitney U-test
was done. Paired matched samples were analysed
with Wilcoxon signed rank test. For correlations
Spearman rank correlation test was used.
P values o0.05 were considered to be statistically
significant.
Results
Patients
A close to perfect match for sampling time post Tx
within the pairs was obtained, only two sample
pairs differed more than 1 month (1.5 and 2
months, respectively). The mean time for the first
sample was 4.5 months (baseline), for the second
sample 7 months (AR and control, respectively),
and for the third sample 12 months (follow up).
Match for gender could not be obtained in three
pairs of patients. Match for type of operation and
preoperative diagnosis could not be obtained in one
pair (Table 1). In one BAL sample we found
respiratory syncytial virus and in one candida,
otherwise all samples were free of infectious
diagnosis.
IL-18 protein in BAL fluid
The mean concentration of IL-18 was not increased
before or during an episode of AR, compared with
the matched control group (Table 2, Fig. 1).
Correspondingly, the difference in IL-18 between
AR and before AR within each subject, did not show
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Table 2 Concentration of soluble of IL-18 protein in BAL fluid (ng/ml).
Mean time after Tx (months) Acute rejection No rejection
4.5 7 12 4.5 7 12
Mean 607 616 510 726 538 543
SD 255 190 277 479 200 193
Median 548 614 399 540 553 529
BAL levels of interleukin-18 161
any difference compared with matched control
subjects.
BAL cells and IL-18
No significant correlation was found for the
concentration of IL-18 and the percentages of cell
subtypes in BAL fluid. Lymphocytosis was seen
during acute rejection (mean 21.8% SD 17.3) versus
non-rejection (mean 10.3% SD 14.0), but this was
not statistically significant. For neutrophils, macro-
phages and eosinophils, no corresponding differ-
ences were found. The relationship between IL-18
and BAL lymphocytes is shown in Fig. 2 ðr ¼
0:23; P40:05Þ: Data for neutrophils, macro-
phages, eosinophils are not shown.
Discussion
This study on matched samples from lungtransplant
recipients could not identify any substantial change
in airway IL-18 during an episode of AR. No
correlation between IL-18 and different inflamma-
tory celltypes in the airways was found.
Although acute rejection is usually treated
sucessfully, it can recur. If immunotherapy is
modulated in the early stage of recurring acute
rejection, a reduced risk for developing oblitera-
tive bronchiolitis could then be achieved.1,2 There-
fore, it is of potential clinical importance to
identify predictive biological markers for the onset
of acute rejection as well as less invasive methods
for the diagnosis of AR other than TBB.
Several pro- and antiinflammatory molecules
have been evaluated as candidates for specific
markers of lung allograft rejection, but no clinically
useful marker has been identified. We expected
that IL-18, a key proinflammatory cytokine aug-
menting the Th1-polarized immune response,8,11,16
would have a potential for being a marker for AR.
Therefore, the current negative findings are some-
what surprising, especially in view of recent data
from subjects undergoing bone marrow transplan-
tation. A four-fold increase in IL-18 levels during
acute graft versus host disease (aGVHD) was
demonstrated after allogen bone marrow trans-
plantation, and high levels of IL-18 strongly
correlated with the severity of disease.17 In our
study, however, we were unable to confirm any
such pattern and this may be due to the role of IL-
18 being more complex. In fact, whilst IL-18 can
enhace NK-cell activity18 and therefore increase
the risk of graft rejection, some results indicate it
may also protect against AR. In a recent study,
depending upon the timepoint when antibodies to
IL-18 was administered in a murine bone marrow
transplantation model, it accelerated aGVHD re-
lated mortality. In contrast, administration of the
actual IL-18 protein significantly improved survival
suggesting that IL-18 may have a regulatory role in
an aggressive systemic alloreaction rather than an
amplifier of the cyokine dysregulation that char-
acterizes aGVHD.19
The interpretation of the inflammatory reaction
during AR in human lungtransplantation is difficult
due to the confounding influence of immunosup-
pressive treatment on inflammatory markers and an
increased propensity for infectious complications
than do other solid organ transplants. In our study,
we therefore used a well-defined patient
material where patients with ARXA2 where identi-
fied and carefully matched with a control group for
age, gender, absence of infection, preoperative
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Figure 1 Individual concentration of IL-18 protein in BAL
fluid at 4.5, 7 and 12 months time after lung transplanta-
tion. Filled dots denote subjects with diagnosis of acute
rejection XA2 at the 7-month interval. Open circles
denote controls without acute rejection.
Figure 2 Correlation of individual concentration of IL-18
in BAL with percentage of lymphocytes in BAL.
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diagnosis, type of operation and time post trans-
plantation. Maintenance immunosuppression did
not differ between the two groups. We therefore
find it unlikely that any major clinical confounder
could have affected our results.
To conclude, this retrospective study does not
exclude that IL-18 is involved in the cellular
response causing AR in lung transplant recipients
but we could not find any evidence that alterations
in the airway concentration of IL-18 are useful for
early detection of AR.
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